BioPharmSignal logoBioPharmSignal

Biotech News

Scholar Rock to Present at Upcoming Investor Conferences

Scholar Rock (SRRK)Scholar RockCompany update

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 27, 2026-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced

Related news

SRRKScholar Rock2026-07-29 12:00 EST

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

SRRKScholar Rock2026-05-26 13:30 EST

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

View all latest news

Scholar Rock

Myostatin Biology Scholar Rock develops therapies that selectively modulate growth factors in their latent forms. Its lead work targets myostatin to improve muscle function while preserving related signaling pathways. Apitegromab Apitegromab is a selective inhibitor of latent myostatin under FDA review for children and adults with spinal...

Recent company news

SRRKScholar Rock2026-09-11 22:25 EST

Scholar Rock Announces FDA Approval of ISEMBYLD™ (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)

SRRKScholar Rock2026-09-02 12:00 EST

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

SRRKScholar Rock2026-08-27 12:00 EST

Scholar Rock to Present at Upcoming Investor Conferences

SRRKScholar Rock2026-08-21 13:06 EST

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

SRRKScholar Rock2026-08-14 20:15 EST

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
49.02 USD
Market cap
5.35B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States